Today: 10 June 2026
Coca-Cola stock slips in New York trade as investors rotate to tech; jobs data looms
6 January 2026
1 min read

Coca-Cola stock slips in New York trade as investors rotate to tech; jobs data looms

New York, Jan 6, 2026, 15:26 EST — Regular session

  • Coca-Cola shares edged lower in afternoon trading, extending an early-2026 slide
  • The stock fell 1.7% on Monday even as broader U.S. indexes gained
  • Traders are watching Friday’s U.S. jobs report and the company’s next earnings update for 2026 guidance

Coca-Cola Co shares (KO) were down 0.1% at $67.87 in afternoon trading on Tuesday.

The stock is coming off a 1.7% drop on Monday, its fourth straight daily decline, and has lagged rivals in recent sessions. PepsiCo fell 1.6% on Monday, while Starbucks rose 3.1% and Mondelez edged up, MarketWatch data showed.

The softness in defensive names such as Coca-Cola has come as the wider market leaned on tech and healthcare, with chip stocks jumping on renewed artificial-intelligence optimism and the Dow hitting a record. “We’re going to have a very strong earnings season for Big Tech,” said Jed Ellerbroek, a portfolio manager at Argent Capital. Reuters

Macro data is also in focus: the U.S. jobs report for December is due at 8:30 a.m. ET on Friday, following JOLTS job openings data on Wednesday, the Labor Department’s release schedule showed.

For Coca-Cola, investors are also looking ahead to the next set of results for updated demand and pricing signals and, crucially, the company’s full-year 2026 outlook. The company said in its most recent quarterly release that it plans to provide full-year 2026 guidance when it reports fourth-quarter earnings.

Coca-Cola has not announced an earnings date yet, but earnings calendars currently point to around Feb. 10.

A risk for the stock is that firmer economic data keeps interest rates higher for longer, which can pressure dividend-paying consumer staples and weigh on valuations across the sector. Richmond Fed President Tom Barkin said on Tuesday the central bank needs “careful” adjustments as it weighs risks to both inflation and employment. Reuters

Next up, traders will parse the U.S. jobs report on Jan. 9 and then look to mid-January Fed signals, including the Beige Book on Jan. 14, before the Fed’s Jan. 27-28 meeting.

Stock Market Today

  • Gold, Silver, Bitcoin Drop as Fed Rate Hike Odds Climb
    June 10, 2026, 9:07 AM EDT. Gold, silver, and bitcoin prices fell sharply on Wednesday as investors recalibrated expectations for U.S. Federal Reserve interest rates. Gold dropped about 2.4% and silver slid up to 2.8% amid fears of higher inflation and a hawkish Fed stance. Traders now see a near-certain chance the Fed will hold rates steady this week but price in a roughly 40% probability of a rate hike by October. Recent stronger U.S. jobs data fueled these bets. Stocks and ETFs linked to precious metals also declined, while bitcoin traded down 1.3%. Analysts note that rising real yields (adjusted for inflation) are creating headwinds for non-yielding assets like gold and silver, despite geopolitical tensions in the Middle East pushing oil prices higher. The European Central Bank is also expected to raise rates, reinforcing the tightening global monetary outlook.

Latest articles

BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

10 June 2026
BlackBerry shares dropped 4.84% to $8.84 Tuesday and slid further to $8.42 premarket Wednesday, erasing part of a 49% rally as investors question whether QNX and Secure Communications growth can justify recent gains ahead of Q1 fiscal 2027 earnings on June 25; the stock is now down 14.5% from last week’s close.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

10 June 2026
Nuvalent soared 39.28% to $123.25 after GSK agreed to buy the company for $124 per share in cash, leaving a narrow 0.6% spread as investors shift focus to the $10.6 billion merger’s tender-offer timing, antitrust review, and FDA decision dates for two lung-cancer drugs in September and November 2026.
Merck stock hits 52-week high as vaccine policy shift and JPM conference loom
Previous Story

Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Synopsys stock climbs as CES automotive push and chip rally lift SNPS shares
Next Story

Synopsys stock climbs as CES automotive push and chip rally lift SNPS shares

Go toTop